Barely Significant
← all excerpts

Temozolomide based treatment in glioblastoma: 6 vs. 12 months.

Oncol Lett · 2024 · PMC11240269 · PMID 39006948

Europe PMCDOI
2
hedged sentences
0.0870
closest p · 1.7× alpha
0.0870
boldest claim

The sentences

a positive trendP=0.087so close (0.05 < p ≤ 0.1)
18.3 months, HR: 0.52, 95%IC 0.23–1.2, P=0.12) and there was also a positive trend for mPFS (14.8 vs. 8.8 months, HR: 0.49, 95%IC 0.22–1.1, P=0.087) without statistical significance ( Fig. 2 ).

also in 3,489 other papers

a small trendno p-value reported
In contrast with these results, no mPFS benefit was found in the unmethylated cohort, with only a small trend in increased survival (12.9 vs. 8.8 months).

also in 161 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.